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Potential advantages of continuous manufacture (CM)
•

Allows for shorter production time (improves patient access)

•

Offers flexibility and agility in response to manufacturing needs (shortages,
supply chain demands)

•

Reduced manufacturing footprint (smaller facilities with higher degree of
automation reduce operator errors, reconfigurable and modular design require
less CapEx and provide added flexibility), reduced inventory

•

Single-use technology and closed processing conditions offer superior protection
against bioburden ingress
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Potential advantages of CM
•

Expedited development with regards to scale-up (no need for comparability
studies and the same equipment can potentially be used in clinical and commercial
manufacturing)

•

Enhanced process understanding and control: On-line monitoring and real time
control of product information assure consistent quality, potential for tighter
control of product quality attributes

•

Enhanced compliance through standardization and application of technology (e.g.
single use technology)
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Scientific and regulatory challenges – certain aspects different
when compared to traditional manufacture – need to be
addressed in a dialogue between regulators and applicants
•

Raw material properties and variability

•

State of control, detection of disturbances

•

Process dynamics

•

Design spaces and potential interactions between steps

•

Material traceability

•

Scalability (equipment design)

•

Evaluation of manufacturing changes & impact on product quality
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Scientific and regulatory challenges
•

Process description may look different when compared to traditional manufacture
(descriptions in terms of material transformation kinetics e.g. flow rates, mean
residence time with associated residence time distribution)

•

The definition of a batch should be stated prior to manufacture

ICH Q7 (EU GMP Guide Part II)
“A specific quantity of material produced in a process or series of processes so that it is
expected to be homogeneous within specified limits. In the case of continuous
production, a batch may correspond to a defined fraction of the production. The batch
size can be defined either by a fixed quantity or by the amount produced in a fixed
time interval”.
7
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Scientific and regulatory challenges
•

Establishment of systems and controls e.g. automated valves, feed-back and feedforward controls

•

Control of material flow rates

•

IPCs and sampling considerations different than batch process

•

Routine use of PAT tools (availability)

•

Use of models (first principles, empirical)

•

Procedures for start up/shut down and interruption of production
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Scientific and regulatory challenges
•

Control strategy is product and process specific, may be different to that for batch
mode

•

Procedures for handling deviations and non-conforming material

•

RTRT: Parallel testing and plan for end product testing when PAT data is not
available (back-up/redundancy)

•

Process validation strategy: traditional process validation or Continuous Process
Verification (CPV), based on data rich environment of PAT-enabled CM

•

Process changes - intermediates not isolated - how to support changes to single
steps?
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Scientific and regulatory challenges
•

Stability of intermediates

•

Life span of filters/ resins etc.?

•

Implementation of Single-Use Technology: Leachable/extractable understanding
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Scientific and regulatory challenges
Design/
engineering
Plans for maintenance?

Strategy for cleaning
validation?
Use of disposable single use
technology?

Location of PAT tools

Equipment

Indicators of equipment
failure?

Potential fouling?
Potential for microbial
growth?

11

Continuous Manufacturing – EMA Perspective and Experience

Location of diverting valves

Regulatory environment
•

ICH Q8, Q9, Q10 and Q11, and PtC: principles apply to enhanced development,
manufacturing and control strategy approaches including CM

•

EU Guideline on Process Validation: introduced CPV

•

EU Guideline on RTRT: more flexibility in batch release (integrated product testing)

•

EU Guideline on manufacture of the finished dosage form: “In case of CM, the
information about batch size in traditional terms might not be relevant; however,
information as to how a batch is defined should be provided (e.g. expressed in
terms of a period of time or a quantity of product, and may be expressed as
ranges)”.
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Regulatory environment
•

EU guideline on Chemistry of new active substances: CM not specifically addressed,
but not in contradiction – applicable to Chem.

•

EU Guideline on Use of NIR: principles applicable to other chemometric models

•

Ph. Eur: chapter on Chemometrics (5.21), NIR (2.2.40), Raman (2.2.48), Large
sample sizes (UDU 2.9.47)

•

Questions and answers: Improving the understanding of NORs, PARs, DSp and
normal variability of process parameters

•

GMP Annex 15 (Qualification and Validation) & Annex 17 RTRT
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Regulatory environment - EMA Guideline on process validation
for finished products - information and data to be provided in
regulatory submissions
Normally performed when pharmaceutical development and/or
process development is concluded, after scale-up to production
scale and prior to marketing (chem.)/approval (biol.) of the
finished product.
Combination of traditional process validation and continuous process verification
approach for different steps within the manufacturing process.
An alternative approach to PV in which manufacturing process performance is
continuously monitored and evaluated. (ICH Q8)
It can be used in addition to, or instead of, traditional process validation. It is a
science and risk-based real-time approach. Extensive in-line, on-line or atline controls and monitor process performance and product quality on each batch.
PAT tools, MSPC. Most appropriate method for validating continuous
processes.
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EMA experience – chemical products
•

Two applications in the centralised procedure (one under the EMA-FDA QbD pilot
program) e. g. Orkambi – continuous manufacture of the finished product

•

Still limited experience (both industry and regulators need to learn more) → EMA
recommends establishing an early dialogue with regulators during CM development

•

Several discussions with companies at PAT team

•

Several scientific advice requests
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EMA experience – biologicals
•

Certain fermentation processes (perfusion cell cultures) may already now be
classified as continuous processes but not named so in the dossiers.

•

Very limited experience with scientific advice requests and MAAs (restricted to
processes with a few manufacturing steps connected with no isolation in-between)
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EMA support to innovation
Objective to develop appropriate and accessible regulatory platforms, tools, incentives
•

CHMP Scientific Advice - official advice from the CHMP on appropriate tests and
studies
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_
content_000049.jsp&mid=WC0b01ac05800229b9)

•

PAT team - The PAT team reviews the implications of quality by design and ensures
that the European regulatory network is prepared for the evaluations of submissions
including quality by design
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing
/document_listing_000162.jsp&mid=WC0b01ac058076ed73)
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EMA support to innovation
Objective to develop appropriate and accessible regulatory platforms, tools, incentives
•

Innovation Task Force (ITF) - platform for early dialogue scientific (Q, NC,
clinical), regulatory and legal points
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_
content_000334.jsp&mid=WC0b01ac05800ba1d9)

•

EMA SME office – dedicated support to small pharmaceutical companies.
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_
content_000059.jsp&mid=WC0b01ac05800240cc)
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Conclusions and recommendations
•

Regulators are supportive of innovative pharmaceutical manufacturing.

•

Current regulatory framework is adequate to allow CM. No specific guideline
currently available, but existing guidance is supportive.

•

CM offers advantages over traditional batch manufacture. Additional considerations
may need to be explored and challenges addressed.

•

Complex dossiers. Level of detail commensurate with impact on the commercial
manufacturing process and control strategy.
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Conclusions and recommendations
•

Dynamic processes – control strategy is key to maintaining state of control,
managing changes and perturbations (and making associated decisions) during
processing and ensuring robust production of material of adequate quality.

•

Regulators need to understand the product and process development,
manufacturing and process control strategy.

•

Adhere to ICH terminology. Provide clear definitions for in-house terms when
unavoidable.

•

Early dialogue with regulators to ensure there is a mutual understanding.
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Thank you!
Any questions?
Further information
Nino.Mihokovic@ema.europa.eu
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